Question-and-Answer Session
Safi Bahcall
I will now open the call to questions and discussion. Operator?
Operator
(Operator Instructions). Our first question is from Joel Sendek of Lazard Capital Markets.
Joel Sendek - Lazard Capital Markets
It appears to me that the biggest risk of the company is that, you might not get the value that 9090 deserves to get and I'm wondering what your plan is to maximize the value of the drug, especially given the responses that we've seen and I guess related to that is, are you doing anything to maybe reduce expenses further until you have one or more of these partnerships in place?
Safi Bahcall
Joel, this is Safi. Yeah, so we're doing both of those things. One is, we've gone through a company wide cost saving initiative where we're really focusing essentially all of our resources on 9090. We're also active with the crack program but that's fully reimbursed by Roche. So essentially all of our, all of the substantial R&D research of the company are focused on advancing 9090 just based on the level of excitement we've seen around that program. That makes a lot of sense for us.
The first part of your question, what are we doing to retain as much value from that program for shareholders, that's something that's absolutely on all of our minds and what we're doing is, we have, as I mentioned we have put ourselves in a fortunate position of having four un-partnered assets. That's just the legacy of the company that we've had generated a number of these drugs and we've seen interest from partners around all four of those programs.
So as I mentioned, we may, it is possible we'll do a large deal around 9090 sooner rather than later but an alternative option, which I think is what you're getting at is we could do some smaller deals sooner and that buys some time to create more value in the 9090 program, advance it further in the clinic and then potentially do a larger deal down the road. So what we're doing is putting all the un-partnered assets of the company in plain discussion with different partners and creating a number of options that could potentially buy us some time with the 9090 to advance it further in the clinic.
Joel Sendek - Lazard Capital Markets
And are you giving yourselves a -- you mentioned mid-2010. Is that a hard deadline or is that just kind of a general goal as to when we might see a deal or two?
- To read the full transcript on Seeking Alpha, click here »
